Risankizumab

Real-world data from a double-center retrospective study demonstrates that both risankizumab and guselkumab maintain high efficacy rates for moderate-to-severe psoriasis over 52 weeks, with PASI90 responses exceeding 90% for both treatments.

Paul Stoffels will retire as Galapagos CEO within 12 months after three years at the helm, during which he transformed the company's focus to cell therapy and oncology through strategic acquisitions.

A new cross-sectional study found that average costs for first-line biologic treatments for plaque psoriasis increased from $21,236 in 2007 to $47,125 in 2021, reflecting a shift toward newer IL-17 and IL-23 inhibitors.

Spyre Therapeutics has dosed the first participant in a Phase 1 trial of SPY003, a half-life extended IL-23 antibody designed for potential quarterly or biannual dosing in inflammatory bowel disease patients.

Recent real-world studies demonstrate that biologics targeting IL-17 and IL-23 are effective for elderly psoriasis patients, with comparable long-term outcomes to younger adults despite initial slower response rates.